Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
post
Last Updated on: 26 December, 2024
Author: Getaka|Social: Getaka Financial Technology X (Earlier Twitter) Profile Getaka Financial Technology LinkedIn Logo

Jubilant Pharmova Ltd: Fundamental Analysis, Share Price Insights & Intrinsic Value (2024)

Share Price and Basic Stock Data

Last Updated: December 26, 2024, 10:10 pm

Market Cap 17,050 Cr.
Current Price 1,070
High / Low 1,310/531
Stock P/E59.9
Book Value 373
Dividend Yield0.47 %
ROCE6.74 %
ROE0.76 %
Face Value 1.00
PEG Ratio-1.07

Stock P/E, Current Price, and Intrinsic Value Over Time

View Share Price Target for Jubilant Pharmova Ltd

Competitors of Jubilant Pharmova Ltd

Stock NameMarket CapCurrent PriceHigh / LowStock P/EBook ValueDividend YieldROCEROEFace Value
MPS Pharmaa Ltd 8.20 Cr. 4.29 4.33/2.79 0.800.00 %9.15 %34.9 % 10.0
Gujarat Themis Biosyn Ltd 3,352 Cr. 308 390/14763.6 20.50.22 %45.0 %33.8 % 1.00
Gujarat Terce Laboratories Ltd 60.9 Cr. 82.1 94.9/26.623.3 11.90.00 %9.72 %3.44 % 10.0
Gujarat Inject (Kerala) Ltd 34.4 Cr. 23.4 27.0/8.7444.6 6.640.00 %2.65 %2.08 % 10.0
Godavari Drugs Ltd 87.5 Cr. 116 155/87.013.1 55.40.00 %14.4 %15.5 % 10.0
Industry Average19,110.67 Cr1,166.2154.93184.740.32%16.14%16.48%6.30

All Competitor Stocks of Jubilant Pharmova Ltd

Quarterly Result

MonthDec 2020Mar 2021Jun 2021Sep 2021Dec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023
Sales1,7711,5801,6351,6571,3111,5281,4521,6001,5521,6781,5871,6801,677
Expenses1,2821,2051,2691,3191,1161,2801,2591,3841,4081,4591,4191,4381,459
Operating Profit490375365338194247192216144219168242218
OPM %28%24%22%20%15%16%13%14%9%13%11%14%13%
Other Income8452446-211-44102191949
Interest46433535374040425156626671
Depreciation96868810093101959494271909795
Profit before tax4312972472087010669369-862598101
Tax %28%28%35%31%28%44%32%87%285%-16%76%37%34%
Net Profit3102141601435159475-16-10066266
EPS in Rs19.4613.4310.088.973.203.742.960.34-0.98-6.150.403.924.19

Last Updated: Unknown

Quarterly Chart

Profit & Loss - Annual Report

Last Updated: Unknown

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023TTM
Sales4,2705,1325,7625,7515,7495,8617,5189,1115,9766,0996,1306,2826,498
Expenses3,3794,1344,7635,1414,4934,5105,9957,3674,4284,6954,9805,5035,724
Operating Profit8919999996101,2561,3521,5221,7441,5481,4031,150779773
OPM %21%19%17%11%22%23%20%19%26%23%19%12%12%
Other Income-318-93-1738641936-2492252638-958
Interest238311337368371341284220200184145188234
Depreciation221254281288347291415371340349382554552
Profit before tax114341207405427388599041,2331,1336302846
Tax %60%45%34%200%29%22%26%36%27%26%34%334%
Net Profit46189138-40387575634577898836413-65-48
EPS in Rs0.919.596.84-3.6324.6036.1440.3536.0656.3952.4725.98-3.83-2.81
Dividend Payout %328%31%43%-83%12%8%7%12%9%10%19%-130%

Profit & Loss Yearly Chart

YoY Net Profit Growth

Year2012-20132013-20142014-20152015-20162016-20172017-20182018-20192019-20202020-20212021-20222022-2023
YoY Net Profit Growth (%)310.87%-26.98%-128.99%1067.50%48.58%10.26%-8.99%55.63%-6.90%-50.60%-115.74%
Change in YoY Net Profit Growth (%)0.00%-337.85%-102.00%1196.49%-1018.92%-38.32%-19.25%64.62%-62.54%-43.69%-65.14%

Jubilant Pharmova Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2012-2013 to 2022-2023.

Growth

Compounded Sales Growth
10 Years:2%
5 Years:-6%
3 Years:3%
TTM:6%
Compounded Profit Growth
10 Years:-14%
5 Years:-44%
3 Years:-64%
TTM:727%
Stock Price CAGR
10 Years:26%
5 Years:18%
3 Years:23%
1 Year:98%
Return on Equity
10 Years:10%
5 Years:7%
3 Years:1%
Last Year:1%

Last Updated: Unknown

Balance Sheet

Last Updated: November 14, 2024, 9:34 pm

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Sep 2024
Equity Capital16151616161616161616161616
Reserves2,4602,6112,4382,9513,4204,0714,7935,5884,7265,3035,3835,4185,925
Borrowings4,2454,3954,7934,4934,0453,4694,8404,8082,8303,1923,6773,6643,080
Other Liabilities1,6501,8421,3721,2801,4171,9021,6701,8981,1921,3191,8532,2402,904
Total Liabilities8,3718,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,33811,924
Fixed Assets4,9675,0994,9115,1045,1075,4015,6486,3404,6094,8715,1835,0915,962
CWIP4374725976116846719017688971,0901,5622,1031,857
Investments26344085103124115692412392564242
Other Assets2,9413,2593,0712,9393,0063,2624,6545,1333,0173,6313,9284,1014,063
Total Assets8,3718,8648,6198,7408,8999,45711,31912,3108,7639,83010,92911,33811,924

Reserves and Borrowings Chart

Cash Flow

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Cash from Operating Activity +9707727831,0991,2681,3031,1221,5431,784838661971
Cash from Investing Activity +-504-164-362-309-465-614-1,018-267-727-323-474-596
Cash from Financing Activity +-450-414-503-843-686-901657-1,050-1,709-33-157-432
Net Cash Flow17194-82-52117-212761225-65248230-58

Free Cash Flow

MonthMar 2012Mar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023
Free Cash Flow891.00995.00995.00606.00-3.00-3.00-2.00-3.00-3.00-1.00-2.00776.00

Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)

Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.

Free Cash Flow Chart

Financial Efficiency Indicators

MonthMar 2013Mar 2014Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024
Debtor Days505152606355517949555650
Inventory Days198200169207223177147463268308268220
Days Payable11510799106137145106273124139160146
Cash Conversion Cycle1331441221621498792268194224165124
Working Capital Days40-16455266576510578867772
ROCE %12%11%6%13%15%15%16%15%12%10%3%7%

Financial Efficiency Indicators Chart

Share Holding Pattern

MonthDec 2021Mar 2022Jun 2022Sep 2022Dec 2022Mar 2023Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024
Promoters50.68%50.68%50.68%50.67%50.67%50.67%50.67%50.67%50.67%50.67%50.67%50.67%
FIIs23.18%23.45%23.47%23.06%23.38%23.22%23.20%23.20%20.29%19.06%19.50%17.94%
DIIs1.06%0.63%0.62%1.60%1.62%1.62%1.63%1.64%2.89%3.77%4.06%5.66%
Government0.00%0.00%0.00%0.00%0.00%1.24%0.00%0.00%0.00%0.00%0.00%0.00%
Public25.01%25.18%25.17%24.59%24.20%23.11%23.91%23.89%25.56%25.91%25.18%25.17%
Others0.07%0.07%0.07%0.07%0.13%0.13%0.59%0.59%0.58%0.58%0.58%0.56%
No. of Shareholders1,09,4201,08,0631,09,4101,05,6321,00,21297,93593,37589,37686,58892,26481,99289,456

Shareholding Pattern Chart

No. of Shareholders

Mutual Fund Holdings

Fund NameNo of SharesAUM (%)Amount Invested (Cr)Previous Number of SharesPrevious DatePercentage Change
Nippon India Pharma Fund550,3390.3720.6146,2102024-12-241090.95%
Nippon India Nifty Smallcap 250 Index Fund46,2100.241.7346,2102024-12-240%
Motilal Oswal Nifty Smallcap 250 Index Fund29,0120.241.0946,2102024-12-24-37.22%
SBI Nifty Smallcap 250 Index Fund21,2920.240.846,2102024-12-24-53.92%
Motilal Oswal Nifty 500 Index Fund3,1700.020.1246,2102024-12-24-93.14%
Edelweiss Nifty Smallcap 250 Index Fund9800.240.0446,2102024-12-24-97.88%
Motilal Oswal S&P BSE Healthcare ETF8270.380.0346,2102024-12-24-98.21%
Groww Nifty Total Market Index Fund1780.020.0146,2102024-12-24-99.61%
Motilal Oswal Nifty 500 ETF1390.020.0146,2102024-12-24-99.7%

ROCE Trend

EPS Trend

Key Financial Ratios

MonthMar 24Mar 23Mar 22Mar 21Mar 20
FaceValue1.001.001.001.001.00
Basic EPS (Rs.)4.87-3.8326.0052.4856.39
Diluted EPS (Rs.)4.86-3.8326.0052.4856.39
Cash EPS (Rs.)27.2529.9850.5573.7077.72
Book Value[Excl.RevalReserv]/Share (Rs.)343.11338.91333.97297.85351.78
Book Value[Incl.RevalReserv]/Share (Rs.)343.11338.91333.97297.85351.78
Revenue From Operations / Share (Rs.)424.23394.85385.08383.10375.13
PBDIT / Share (Rs.)61.3651.2073.3588.8399.52
PBIT / Share (Rs.)37.1916.3849.3766.9178.19
PBT / Share (Rs.)9.270.9740.2354.0163.58
Net Profit / Share (Rs.)3.08-4.8526.5751.7856.39
NP After MI And SOA / Share (Rs.)4.88-3.8326.0052.5156.39
PBDIT Margin (%)14.4612.9619.0423.1826.52
PBIT Margin (%)8.764.1412.8217.4620.84
PBT Margin (%)2.180.2410.4414.0916.94
Net Profit Margin (%)0.72-1.226.9013.5115.03
NP After MI And SOA Margin (%)1.15-0.976.7513.7015.03
Return on Networth / Equity (%)1.41-1.127.7817.6216.02
Return on Capital Employeed (%)6.082.779.3513.5312.57
Return On Assets (%)0.66-0.544.149.377.17
Long Term Debt / Equity (X)0.580.570.460.540.66
Total Debt / Equity (X)0.620.630.550.540.78
Asset Turnover Ratio (%)0.590.590.010.370.37
Current Ratio (X)2.052.122.202.811.92
Quick Ratio (X)1.371.341.421.741.22
Inventory Turnover Ratio (X)1.361.260.001.441.62
Dividend Payout Ratio (NP) (%)103.24-130.6019.230.0016.84
Dividend Payout Ratio (CP) (%)17.3416.1510.000.0012.22
Earning Retention Ratio (%)-3.24230.6080.770.0083.16
Cash Earning Retention Ratio (%)82.6683.8590.000.0087.78
Interest Coverage Ratio (X)3.564.338.037.687.94
Interest Coverage Ratio (Post Tax) (X)1.800.893.914.174.56
Enterprise Value (Cr.)11426.806827.698114.6012743.976953.89
EV / Net Operating Revenue (X)1.701.091.322.091.16
EV / EBITDA (X)11.798.386.959.014.39
MarketCap / Net Operating Revenue (X)1.340.701.011.780.66
Retention Ratios (%)-3.24230.6080.760.0083.15
Price / BV (X)1.650.821.162.280.70
Price / Net Operating Revenue (X)1.340.701.011.780.66
EarningsYield0.01-0.010.060.070.22

Profitability Ratios (%)

Liquidity Ratios

Liquidity Ratios (%)

Interest Coverage Ratios (%)

Valuation Ratios

Fair Value

Fair Value of Jubilant Pharmova Ltd as of December 26, 2024 is: 170.60

Calculation basis:

  • Fair value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.

This formula allows us to gauge the fair value of the stock by analyzing its fundamental indicators.

As of December 26, 2024, Jubilant Pharmova Ltd is Overvalued by 84.06% compared to the current share price 1,070.00

Intrinsic Value of Jubilant Pharmova Ltd as of December 26, 2024 is: 75.17

Calculation basis:

  • Intrinsic value = P/E Ratio * (Return on Equity / 100) * Book Value * (1 + Dividend Yield / 100) * (1 + EPS CAGR for Last 5 Years)
  • P/E Ratio (Price-to-Earnings Ratio): Represents the price of the stock relative to its earnings per share. A higher P/E ratio indicates that investors are willing to pay a higher price for the stock.
  • Return on Equity (ROE): Measures a company's profitability relative to its shareholder equity. It showcases the company's ability to generate profits using the investment made by its shareholders, offering valuable insight into its operational efficiency and financial performance.
  • Book Value: Represents the net asset value of the company per share. It is calculated as the total assets minus intangible assets and liabilities, divided by the number of outstanding shares.
  • Dividend Yield: The ratio of the annual dividend per share to the current market price per share. It offers valuable insights into the profitability of an investment through dividends.
  • EPS CAGR (Compound Annual Growth Rate): Represents the geometric mean growth rate of earnings per share over the last 5 years. It provides insight into the historical growth trajectory of the company's earnings.

This formula allows us to gauge the intrinsic value of the stock by analyzing its fundamental indicators along with EPS growth.

As of December 26, 2024, Jubilant Pharmova Ltd is Overvalued by 92.97% compared to the current share price 1,070.00

Last 5 Year EPS CAGR: -55.94%

*Investments are subject to market risks

Strength and Weakness

StrengthWeakness
  1. The company has higher reserves (4,237.46 cr) compared to borrowings (3,963.92 cr), indicating strong financial stability.
  2. The company has shown consistent growth in sales (5.69 cr) and profit (342.38 cr) over the years.
  1. The stock has a low average ROCE of 11.25%, which may not be favorable.
  2. The stock has a high average Working Capital Days of 60.58, which may not be favorable.
  3. The stock has a high average Cash Conversion Cycle of 155.33, which may not be favorable.

Stock Analysis

  • Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Jubilant Pharmova Ltd:
    1. Net Profit Margin: 0.72%
      • Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
    2. ROCE: 6.08% (Industry Average ROCE: 16.01%)
      • ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
    3. ROE%: 1.41% (Industry Average ROE: 15.93%)
      • ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
    4. Interest Coverage Ratio (Post Tax): 1.8
      • Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
    5. Quick Ratio: 1.37
      • Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
    6. Stock P/E: 59.9 (Industry average Stock P/E: 44.77)
      • Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
    7. Total Debt / Equity: 0.62
      • Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
    The current analysis is available for review. It's important to conduct thorough research and consider consulting with financial professionals before making any investment decisions.
    Stock Rating:

About the Company - Qualitative Analysis

Jubilant Pharmova Ltd. is a Public Limited Listed company incorporated on 21/06/1978 and has its registered office in the State of Uttar Pradesh, India. Company’s Corporate Identification Number(CIN) is L24116UP1978PLC004624 and registration number is 004624. Currently Company is involved in the business activities of Manufacture of basic chemicals. Company’s Total Operating Revenue is Rs. 87.75 Cr. and Equity Capital is Rs. 15.93 Cr. for the Year ended 31/03/2022.
INDUSTRYADDRESSCONTACT
PharmaceuticalsBhartiagram, Amroha District Uttar Pradesh 244223investors@jubl.com
http://www.jubilantpharmova.com
Management
NamePosition Held
Mr. Shyam S BhartiaChairman
Mr. Hari S BhartiaCo-Chairman
Mr. Priyavrat BhartiaManaging Director
Mr. Arjun Shanker BhartiaJoint Managing Director
Mr. Arvind ChokhanyWholeTime Director & Group CFO
Dr. Ramakrishnan ArulWhole Time Director
Mr. Shirish G BelapureIndependent Director
Mr. Sushil Kumar RoongtaIndependent Director
Mr. Vivek MehraIndependent Director
Mr. Arun SethIndependent Director
Dr. Harsh MahajanIndependent Director
Ms. Shivpriya NandaIndependent Director

FAQ

What is the latest intrinsic value of Jubilant Pharmova Ltd?

The latest intrinsic value of Jubilant Pharmova Ltd as on 26 December 2024 is ₹170.60, which is 84.06% lower than the current market price of ₹1,070.00. The stock has a market capitalization of 17,050 Cr. and recorded a high/low of 1,310/531 during the current fiscal year 2024-2025. As of Sep 2024, the company has reserves of ₹5,925 Cr and total liabilities of ₹11,924 Cr.

What is the Market Cap of Jubilant Pharmova Ltd?

The Market Cap of Jubilant Pharmova Ltd is 17,050 Cr..

What is the current Stock Price of Jubilant Pharmova Ltd as on 26 December 2024?

The current stock price of Jubilant Pharmova Ltd as on 26 December 2024 is 1,070.

What is the High / Low of Jubilant Pharmova Ltd stocks in FY 2024-2025?

In FY 2024-2025, the High / Low of Jubilant Pharmova Ltd stocks is 1,310/531.

What is the Stock P/E of Jubilant Pharmova Ltd?

The Stock P/E of Jubilant Pharmova Ltd is 59.9.

What is the Book Value of Jubilant Pharmova Ltd?

The Book Value of Jubilant Pharmova Ltd is 373.

What is the Dividend Yield of Jubilant Pharmova Ltd?

The Dividend Yield of Jubilant Pharmova Ltd is 0.47 %.

What is the ROCE of Jubilant Pharmova Ltd?

The ROCE of Jubilant Pharmova Ltd is 6.74 %.

What is the ROE of Jubilant Pharmova Ltd?

The ROE of Jubilant Pharmova Ltd is 0.76 %.

What is the Face Value of Jubilant Pharmova Ltd?

The Face Value of Jubilant Pharmova Ltd is 1.00.

About the Author

Author Avatar
Getaka

Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.

Disclaimer: This article is for informational purposes only and should not be construed as financial advice. The author is not a SEBI registered financial advisor and does not have any vested interest in Jubilant Pharmova Ltd. Investors are advised to conduct their own due diligence and consult with a financial professional before making any investment decisions. The information provided in this article is based on publicly available data and the author's analysis, but it may not be comprehensive or up-to-date. The author and getaka.co.in are not responsible for any errors or omissions in the content. This article is not intended to promote any particular investment strategy or recommendation, and readers should consult with their own financial advisors before making any investment decisions. Data Source: NSE